Survodutide Shows Significant Weight Loss and Liver Health Benefits in Phase 3 Trials

Survodutide, a once-weekly injectable dual glucagon/GLP-1 receptor agonist, has demonstrated substantial efficacy in reducing body weight and liver fat content in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Recent data from the phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials, presented at the American Diabetes Association Scientific Sessions in June 2026, indicate that the drug provides meaningful improvements in cardiometabolic health markers.

Efficacy in Weight Management: The SYNCHRONIZE-1 Trial

The SYNCHRONIZE-1 trial evaluated 725 adults with overweight or obesity who did not have type 2 diabetes. According to findings published in The New England Journal of Medicine, participants receiving survodutide experienced significant weight loss over 76 weeks. Those treated with the 6 mg dose achieved a mean weight reduction of 16.6%, while those on the 3.6 mg dose saw a 15.3% reduction, compared to a 3.2% change in the placebo group.

Beyond body weight, the trial measured secondary metabolic improvements. Carel le Roux, MD, PhD, of University College Dublin, reported that waist circumference decreased by approximately 14 cm among participants in the survodutide groups. Additionally, an MRI substudy revealed a 63.1% reduction in liver fat content and a 34% reduction in visceral adipose tissue at the highest dose.

Impact on Liver Health and MASLD

The SYNCHRONIZE-MASLD trial focused specifically on 216 adults with overweight or obesity and risk for MASLD. Published simultaneously in Nature Medicine, the study revealed that 84.2% of participants receiving 6 mg of survodutide achieved a 30% or greater reduction in liver fat content at 48 weeks, compared to 24.3% in the placebo group. Lee M. Kaplan, MD, PhD, of the Geisel School of Medicine at Dartmouth, noted that the treatment normalized liver fat content in 60% of those receiving the medication.

The trial also demonstrated improvements in liver fibrosis markers and serum transaminases. Participants in this study included those with type 2 diabetes, and the treatment group showed consistent improvements in cardiometabolic risk factors, including blood pressure, HbA1c levels, and lipid profiles.

Safety Profile and Clinical Considerations

The safety profile observed in both trials aligned with the known characteristics of the GLP-1 receptor agonist class. The most frequently reported adverse events were mild to moderate gastrointestinal symptoms. According to the trial data, 19.9% of participants in the SYNCHRONIZE-MASLD trial and up to 24.8% in the SYNCHRONIZE-1 trial discontinued treatment due to these gastrointestinal side effects.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, emphasized that the medical community is moving toward a focus on multiorgan health rather than weight loss alone. Future research is expected to clarify long-term cardiovascular outcomes and the specific patient populations most likely to benefit from this dual-agonist approach.

Key Takeaways

• Weight Reduction: Survodutide led to mean weight loss of approximately 15% to 16% in phase 3 studies.
• Liver Health: The drug significantly reduced liver fat content, with 60% of MASLD trial participants reaching normalized levels.
• Metabolic Markers: Participants experienced improvements in blood pressure, cholesterol, and glycemic control.
• Common Side Effects: Gastrointestinal symptoms were the primary cause of trial discontinuation, consistent with other GLP-1-based therapies.

Disclosure: The SYNCHRONIZE trials were funded by Boehringer Ingelheim. Study investigators report various consulting relationships with pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.